CN112358547A - Anti-human CXCL-2 monoclonal antibody 3-D3 and coding gene and application thereof - Google Patents
Anti-human CXCL-2 monoclonal antibody 3-D3 and coding gene and application thereof Download PDFInfo
- Publication number
- CN112358547A CN112358547A CN202011066422.0A CN202011066422A CN112358547A CN 112358547 A CN112358547 A CN 112358547A CN 202011066422 A CN202011066422 A CN 202011066422A CN 112358547 A CN112358547 A CN 112358547A
- Authority
- CN
- China
- Prior art keywords
- cxcl
- monoclonal antibody
- antibody
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention belongs to the technical field of bioengineering, and relates to an anti-human CXCL-2 monoclonal antibody 3-D3, and a coding gene and application thereof. The monoclonal antibody or the fragment thereof is combined with an extracellular region containing a chemotactic factor CXCL-2 and has the function of blocking the CXCL-2, and the invention relates to an antihuman CXCL-2 monoclonal antibody and preparation thereof, a variable region amino acid sequence and a gene coding sequence and application thereof. The invention newly finds a monoclonal antibody capable of blocking the function of human chemotactic factor CXCL-2 and a coding gene thereof, the antibody can be combined with the extracellular region of human CXCL-2, can specifically block the combination of CXCL-2 and a ligand thereof, and inhibits signal transduction, so that the monoclonal antibody can be used as a blocking agent of a CXCL-2 signal channel, thereby becoming a novel antibody medicine for treating tumor immunotherapy, acute and chronic infectious diseases and autoimmune diseases.
Description
Technical Field
The invention belongs to the technical field of bioengineering, and relates to an anti-human CXCL-2 monoclonal antibody, a preparation method thereof, a variable region amino acid sequence, a gene coding sequence and application thereof, wherein the monoclonal antibody or a fragment thereof is combined with an extracellular region containing a chemotactic factor CXCL-2 and has the function of blocking the CXCL-2 function.
Background
Chemokines are a class of proteins that regulate leukocyte migration and play an important role in inflammatory responses, and in 1988, Cerami et al performed purification analysis of two heparin-binding proteins released from macrophages stimulated by LPS and found MIP-1[ Wolpe SD, Davatelis G, Sherry B, Beutler B, Hesse DG, Nguyen HT, et al. macrophages secrete a novel heparin-binding protein with affinity and neutrophilic chemical properties. the Journal of experimental media.1988; 167:570-81 ], the next year, CXCL-2 was isolated and its molecular structure and biological activity were tested [ Wolpe SD, Sherry B, Juers D, Davatelis G, Yurt RW, Cerami A. identification and characterization of macromolecular in fluorescence protein 2.Proceedings of the National Academy of science of the United States of America.1989; 86:612-6.]. Unlike MIP-1, CXCL-2 is a basic heparin binding protein with a molecular weight of about 6000 Kd. The murine CXCL-2 molecule has 4 exons and three introns, a structure typical of the platelet factor 4 (PF 4) subfamily, but partial N-terminal amino acid sequence analysis of the CXCL-2 molecule reveals that the mouse CXCL-2 sequence has 62.5% and 68.7% homology with human and hamster GROs, respectively [8 ]. Murine CXCL-2 is a neutrophil chemokine that belongs to the IL-8 family, and in 1993, Watanabe K et al found that the neutrophil chemotactic cytokine CXCL-2 in LPS-induced inflammatory rat inflammatory secretions has a higher similarity to human gro/MGSA than to IL-8[9 ].
CXCL-2 is a main chemotactic factor and an activating factor of neutrophilic granulocyte, and researches show that the expression of CXCL-2mRNA is remarkably increased in a rat inflammation model and is positively correlated with the chemotactic infiltration quantity of the neutrophilic granulocyte in a rat body, and the secretion of TNF-alpha in the abdominal cavity of the rat can be remarkably increased by injecting recombinant CXCL-2 protein into the abdominal cavity of the rat [36 ]. Blockade of CXCL-2 in vivo can lead to a decrease in the number of neutrophil infiltrates and a reduction in the inflammatory response of the body [ 37 ]. In acute pneumonia rat model CXCL-2 can chemotaxis neutrophils to lung inflammation position and activated, and participates in lung tissue inflammation [ 39 ]. In a mouse model of pseudomonas aeruginosa infection, CXCL-2 secreted by inflammatory tissues can lead to long-term recruitment and chemotaxis of polymorphonuclear neutrophils, constituting irreversible destruction of tissue [ 40 ]. The chemokine CXCL-2 can participate in the migration of neutrophils to the liver of a mouse through a P2Y2 receptor, and the CXCL-2 antibody can inhibit the chemotaxis of the neutrophils in the peritoneal exudate of a peritonitis mouse [ 34, 41 ]. Taken together, CXCL-2 plays an important role in the recruitment of neutrophils to the chemotactic process of the liver and other organs in inflammatory states.
The existing CXCL-2 antibodies are low in affinity, and a blocking CXCL-2 antibody with high affinity is still absent.
Disclosure of Invention
In order to solve the problems, the invention discloses a monoclonal antibody or a fragment thereof for resisting human CXCL-2, wherein the monoclonal antibody or the fragment thereof can be specifically combined with human CXCL-2 protein and has a functional effect of blocking a CXCL-2 protein signal channel.
The monoclonal antibody comprises a light chain and a heavy chain, the amino acid variable region sequences of the monoclonal antibody are respectively shown as SEQ ID NO 7 and SEQ ID NO 8 in a sequence table, and the coding gene sequences of the monoclonal antibody are respectively shown as SEQ ID NO 9 and SEQ ID NO 10 in the sequence table.
Amino acid sequence of light chain variable region of NO 7
1
AspIleGlnLeuThrGlnSerProAlaSerLeuAlaValSerLeuGlyGlnArgAlaThr
21
IleSerTyrArgAlaSerLysSerValSerThrSerGlyTyrSerTyrMETHisTrpAsn
41
GlnGlnLysProGlyGlnProProArgLeuLeuIleTyrLeuValSerAsnLeuGluSer
61
GlyValProAlaArgPheSerGlySerGlySerGlyThrAspPheThrLeuAsnIleHis
81
ProValGluGluGluAspAlaAlaThrTyrTyrCysGlnHisIleArgGluLeuThrArg
101 SerGluGlyGlyProSerTrpArgSerAsn
Amino acid sequence of heavy chain variable region of NO 8
1
ValLysLeuGlnGlnSerGlyProGluLeuLysLysProGlyGluThrValLysIleSer
21
CysLysAlaSerGlyTyrThrPheThrHisTyrGlyIleAsnTrpValThrGlnAlaPro
41
GlyLysGlyLeuLysTrpMETGlyTrpIleAsnThrAsnThrGlyGluProThrTyrAla
61
GluGluPheLysGlyArgPheAlaPheSerLeuGluMETSerAlaSerThrAlaTyrLeu
81
GlnIleAsnAsnLeuLysAsnGluAspThrAlaThrTyrPheCysAlaArgLeuGluVal
101 ArgGlyTyrAlaMETAspTyrTrpGlyGlnGlyThrThrValThrValSerSer
NO 9 light chain variable region DNA sequence
10 heavy chain variable region DNA sequence
The amino acid sequences of the complementarity determining region CDR1-3 of the monoclonal antibody light chain variable region are respectively shown in sequence tables SEQ ID NO:1 and SEQ ID NO: 2. SEQ ID NO. 3. The amino acid sequences of the complementarity determining region CDR1-3 of the heavy chain variable region of the monoclonal antibody are respectively shown in the sequence tables SEQ ID NO:4 and SEQ ID NO: 5. SEQ ID NO. 6.
LysSerValSerThrSerGlyTyrSerTyr
Amino acid sequence of complementarity determining region 2(CDR2) in light chain variable region of NO 2
LeuValSerAsn
Amino acid sequence of complementarity determining region 3(CDR3) in light chain variable region of NO 3
GlnHisIleArgGluLeuThrArg
Amino acid sequence of complementarity determining region 1(CDR1) of heavy chain variable region of NO 4
GlyTyrThrPheThrHisTyrGly
Amino acid sequence of complementarity determining region 2(CDR2) of heavy chain variable region of NO 5
TrpIleAsnThrAsnThrGly
Amino acid sequence of complementarity determining region 3(CDR3) of heavy chain variable region of NO 6
CysAlaArgLeuGluValArgGlyTyrAlaMETAsp
The monoclonal antibody or an antibody fragment thereof of the present invention may be any of a single-chain antibody, a diabody, a chimeric antibody, a humanized antibody, and a derivative, a functional equivalent or a homologue of the above antibody, as long as it can bind to a human CXCL-2 protein and has a functional effect capable of blocking the CXCL-2 pathway.
The invention discloses a monoclonal antibody for blocking the function of human chemotactic factor CXCL-2, and a coding gene and application thereof. It comprises a light chain and a heavy chain, wherein the amino acid sequence of the light chain is shown as (NO:7), and the amino acid sequence of the heavy chain is shown as (NO: 8). The invention newly finds a monoclonal antibody capable of blocking the function of human chemotactic factor CXCL-2 and a coding gene thereof, the antibody can be combined with the extracellular region of human CXCL-2, can specifically block the combination of CXCL-2 and a ligand thereof, and inhibits signal transduction, so that the monoclonal antibody can be used as a blocking agent of a CXCL-2 signal channel, thereby becoming a novel antibody medicine for treating tumor immunotherapy, acute and chronic infectious diseases and autoimmune diseases.
Drawings
FIG. 1 is an agarose gel electrophoresis of the light and heavy chain variable region gene of anti-human CXCL-2 monoclonal antibody 3-D3 amplified by RT-PCR, wherein M is DM1000 DNA marker, L represents the light chain variable region gene, and H represents the heavy chain variable region gene.
FIG. 2 shows an animal experiment of a mouse with hepatitis of 3-D3 monoclonal antibody against human CXCL-2, in which a galactosamine-induced acute hepatitis mouse model treated with 3-D3 antibody has reduced ALT and AST contents in peripheral blood of the mouse and significantly reduced inflammation of the mouse.
Detailed Description
Example 1: construction of hybridoma cell lines
1. Material
DNA immunoadjuvants were purchased from Sigma; fetal bovine serum and PRMI1640 medium were purchased from Gibco; SP2/0 cells were purchased from ATCC; BALB/c mice were provided by the Experimental animals center of university of Zhejiang.
2. The method comprises the following steps:
(1) plasmid construction
The primers are designed according to the CXCL-2 gene sequence searched at NCBI, the DNA sequence of the CXCL-2 gene is amplified by taking human cDNA as a template, and the DNA sequence is constructed on pcDNA3.1 plasmid by utilizing a molecular biology method.
(2) Immunization of mice
BALB/c mice of 4-6 weeks old are selected, the constructed CXCL-2 gene recombinant plasmid is dissolved in PBS and mixed with adjuvant in equal volume for emulsification, and subcutaneous and abdominal multipoint immunization is carried out. Every 2 weeks after the first immunization, the plasmid and the adjuvant with the same dose are mixed and emulsified respectively, and then injected for boosting immunization. After 7 days of 3 rd immunization, tail vein blood was collected and subjected to gradient dilution by ELISA method to detect the antibody production. 3 days before fusion, the same dose of plasmid was mixed with adjuvant and boosted 1 time.
(3) Cell fusion
After the immunized mouse is killed, the spleen of the mouse is picked up aseptically, a single cell suspension is prepared by grinding, and the number of cells is counted after the single cell suspension is washed twice by RPMI1640 culture solution; mixing mouse spleen lymphocyte and myeloma cell SP2/0 at a ratio of 1:5-1:10, slowly adding 1ml of 50% PEG solution dropwise in a short time, placing in 37 deg.C water bath for 1min, adding RPMI1640 culture solution, centrifuging at 800r/min for 5min, discarding supernatant, adding 1640 culture medium containing 20% FBS to suspend cells, mixing the cell suspension with equal volume of feedMixing cultured cells (mouse abdominal cavity macrophages), subpackaging into 96-well cell culture plates, standing at 37 deg.C with 5% CO2Culturing in an incubator. After 3d of culture, HAT 1640 containing 20% FBS was added for selection medium culture.
(4) Screening of hybridoma cells
When the cell colony of the 96-well plate grows to a proper size, the cell culture supernatant is extracted and detected by an indirect ELISA method, and positive hybridoma cells are screened.
(5) Hybridoma cell cloning
When the hybridoma cells identified as positive were cultured to good condition, the cells were diluted and plated into 96-well plates by limiting dilution so that only one cell was present in each well, and the cells were incubated at 37 ℃ in 5% CO2Culturing in an incubator. Observing the cell growth condition in 5d-10d, taking the supernatant in the hole forming single cell clone, detecting by using an indirect ELISA method, screening and identifying positive clone; and repeating the subcloning for 3-5 times until the positive porosity of the hybridoma cells reaches 100%, and determining the stability of the cells.
Example 2: antibody subclass identification and stability test
The subclass of the antibody is identified by referring to the specification of the antibody subclass identification kit, and as a result, the heavy chain class is IgG1 type, and the light chain is Kappa type.
Continuously subculturing the hybridoma cell strain in vitro for 3 months, and measuring the titer of the antibody in the supernatant; the cryopreserved hybridoma cell strain is recovered after 4 months, and the antibody titer in the supernatant is detected without obvious change, which shows that the obtained hybridoma cell strain generating the antibody has stable performance.
Example 3: experiment for inhibiting migration of neutrophils by anti-CXCL-2 monoclonal antibody
1. Material
2. Method and results
(1) Matrix glue common plate: the upper surface of the bottom membrane of the Transwell cell was coated by diluting with Matrigel 1:8 from BD, and the Matrigel was polymerized into a gel at 37 ℃ for 30min before use to hydrate the substrate membrane.
(2) Preparation of cell suspensions
(3) Seeding cells
100ul of the decellularized suspension was placed in a Transwell chamber, and 600ul of 20% FBS-containing medium was typically placed in the lower chamber of a 24-well plate, and cultured for 24 hours
(4) And (5) counting the results. The Transwell chamber was removed, the medium from the wells was discarded, washed 2 times with calcium-free PBS, fixed with formaldehyde for 30 minutes, and the chamber was appropriately air-dried. 0.1% crystal violet staining for 20min, gently rubbing off the upper layer of non-migrated cells with a cotton swab, washing 3 times with PBS, observing the cells with 5 visual fields under 400-fold microscope, and counting.
Example 4: cloning of heavy and light chains of the CXCL-2 monoclonal antibody
1. Material
Designing amplification primers of heavy chain and light chain according to the gene sequence of the vector in Hangzhou Ongke Biotechnology GmbH; the DNA fragment purification kit and the plasmid extraction kit are purchased from QIAGEN company; pMD-18T kit, reverse transcriptase and Fidelity PCR enzymes were purchased from TAKARA; competent cells were purchased from promega; trizol reagent was purchased from Invitrogen corporation.
2. Method and results
(1) Take 5X 106-107And centrifuging the monoclonal antibody hybridoma cells to remove supernatant, adding 1ml of Trizol reagent, and repeatedly blowing and beating until the cells are fully lysed. Standing at room temperature for 5min, adding 0.2ml chloroform, mixing by turning upside down, and standing at room temperature for 2-3 min. Centrifuge at 12000 × g for 15min at 4 ℃. Carefully suck the supernatant and mix with another centrifuge tube, add 500. mu.l isopropanol, mix well by inversion, then stand at room temperature for 10min, centrifuge at 12000 × g at 4 ℃ for 10 min. Adding 1ml of precooled 75% ethanol to wash the precipitate, centrifuging 7500 x g for 5min, then discarding the supernatant, drying at room temperature for 5min, and adding RNase-free deionized water to dissolve the precipitate.
(2) Adding 1 mu L of random primer into 1 mu g of RNA, supplementing the random primer to 6 mu L with RNase-free water, quickly placing on ice for 2min after incubating for 10min at 70 ℃, adding 5M-MLV Buffer 2 mu L, dNTP mix 0.5 mu L, RNase inhibitor 0.25 mu L, M-MLV enzyme 1 mu L and RNase-free water to 10 mu L, incubating for 1h at 42 ℃, incubating for 15min at 70 ℃, and cooling on ice to obtain a product which is a first strand cDNA.
(3) In an amplification system of 25. mu.L, 0.5. mu.L of each of two pairs of heavy chain and light chain PCR amplification primers, 2. mu.L of a reverse transcription product, 0.5. mu.L of a high fidelity PCR amplification enzyme, 2. mu.L of dNTP and 5. mu.L of Buffer are respectively added, and water is used for complementing the mixture to 25. mu.L. The PCR amplification parameters were: pre-denaturation at 94 ℃ for 2min, cyclic procedure: 35 cycles of 98 ℃ 10s 55 ℃ 30s 68 ℃ 30 s.
(4) PCR amplification products run agarose gel, the desired target products are reclaimed by tapping, after being reclaimed by a DNA fragment reclaiming kit, the DNA fragments and the carrier are mixed according to the molar ratio of 10:1 according to the specification of a pMD-18T kit, and then ligase and connecting Buffer are added, the total volume is 10 mu L, and the overnight connection is carried out at 16 ℃.
(5) Adding 10 μ L of the connecting liquid into 200 μ L of TOP 10F' competent bacteria, ice-cooling for 30min, heat-shocking at 42 ℃ for 90s, rapidly placing on ice for 2min, adding 800 μ L of LB culture liquid, shaking and culturing at 37 ℃ and 180rpm/min for 45min, centrifuging at 5000rpm for 2min, discarding about 800 μ L of supernatant, blowing the precipitate uniformly with the rest liquid, spreading on LB solid culture medium plate containing ampicillin, and inversely culturing the plate in a 37 ℃ culture box for 12-16 h. Selecting a single bacterial clone from a plate, inoculating the bacterial clone into an LB liquid culture medium containing ampicillin, carrying out shaking culture at 37 ℃ and 220rpm/min for overnight, removing part of bacterial liquid, cracking, carrying out PCR amplification verification by using light chain and heavy chain primers, and amplifying bacterial liquid with fragments with required sizes to carry out sequencing. After the bacterial liquid with correct sequencing is transferred, a DNA plasmid extraction kit is used for extracting plasmids which carry genes of heavy chains and light chains of variable regions of antibodies.
Example 5: hepatitis mouse animal experiment of anti-human CXCL-2 monoclonal antibody 3-D3
Male C57BL/6 mice, 7 weeks old and 18-20g in weight, were prepared and fasted for 12h before the start of the experiment without water deprivation. The mice were weighed according to the labeled numbers to record the body weights, and were divided into 4 groups, namely a blank control group, an acute hepatitis mouse model group, a high concentration antibody group (100 ug/mouse), and a low concentration antibody group (25 ug/mouse). Anti-human CXCL-2 monoclonal antibodies were prepared using physiological saline, and the antibodies were injected into the mice of the high concentration antibody group (100 ug/mouse) and the low concentration antibody group (25 ug/mouse) by intraperitoneal injection of the mice. After 1 hour, LPS/D-GaIN mixed solutions with final concentrations of 1ug/ml and 100mg/kg were prepared, and the LPS/D-GaIN mixed solutions were injected into mice of the acute hepatitis mouse model group, the high concentration antibody group (100 ug/mouse), and the low concentration antibody group (25 ug/mouse) by intraperitoneal injection. After the model building is finished according to the time needed by the model building, 5 percent sodium pentobarbital is injected into the abdominal cavity of the anesthetized mouse in sequence, the eyeball takes blood, the supernatant is obtained by centrifugation, and the concentration of alanine Aminotransferase (ALT) and aspartate Aminotransferase (AST) in the serum is detected.
Sequence listing
<110> Zhejiang university
<120> antihuman CXCL-2 monoclonal antibody 3-D3, and coding gene and application thereof
<160> 10
<170> SIPOSequenceListing 1.0
<210> 2
<211> 10
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr
1 5 10
<210> 2
<211> 4
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Leu Val Ser Asn
1
<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Gln His Ile Arg Glu Leu Thr Arg
1 5
<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Gly Tyr Thr Phe Thr His Tyr Gly
1 5
<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Trp Ile Asn Thr Asn Thr Gly
1 5
<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 6
Cys Ala Arg Leu Glu Val Arg Gly Tyr Ala Asp
1 5 10
<210> 7
<211> 112
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 7
Ala Ile Gly Leu Thr Gly Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Gly Ala Ala Thr Ile Ser Thr Ala Ala Ser Leu Ser Val Ser Thr Ser
20 25 30
Gly Thr Ser Thr Met Glu Thr His Thr Ala Gly Gly Leu Pro Gly Gly
35 40 45
Pro Pro Ala Leu Leu Ile Thr Leu Val Ser Ala Leu Gly Ser Gly Val
50 55 60
Pro Ala Ala Pro Ser Gly Ser Gly Ser Gly Thr Ala Pro Thr Leu Ala
65 70 75 80
Ile His Pro Val Gly Gly Gly Ala Ala Ala Thr Thr Thr Cys Gly His
85 90 95
Ile Ala Gly Leu Thr Ala Ser Gly Gly Gly Pro Ser Thr Ala Ser Ala
100 105 110
<210> 8
<211> 115
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 8
Val Lys Leu Gln Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu Thr
1 5 10 15
Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr His Tyr Gly
20 25 30
Ile Asn Trp Val Thr Gln Ala Pro Gly Lys Gly Leu Lys Trp Gly Trp
35 40 45
Ile Asn Thr Asn Thr Gly Glu Pro Thr Tyr Ala Glu Glu Phe Lys Gly
50 55 60
Arg Phe Ala Phe Ser Leu Glu Ser Ala Ser Thr Ala Tyr Leu Gln Ile
65 70 75 80
Asn Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys Ala Arg Leu
85 90 95
Glu Val Arg Gly Tyr Ala Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
100 105 110
Val Ser Ser
115
<210> 9
<211> 285
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
tgcttcctta gctgtatctc tggggcagag ggccaccatc tcatacaggg ccagcaaaag 60
tgtcagtaca tctggctata gttatatgca ctggaaccaa cagaaaccag gacagccacc 120
cagactcctc atctatcttg tatccaacct agaatctggg gtccctgcca ggttcagtgg 180
cagtgggtct gggacagact tcaccctcaa catccatcct gtggaggagg aggatgctgc 240
aacctattac tgtcagcaca ttagggagct tacacgttcg gaggg 285
<210> 10
<211> 301
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
acctgagttg aagaagcctg gagagacagt caagatctcc tgcaaggctt ctggatatac 60
cttcacacac tatggaatca attgggtgac gcaggctcca ggaaagggtt taaagtggat 120
gggctggata aacaccaaca ctggagagcc aacatatgct gaagagttca agggacgatt 180
tgccttctct ttggaaatgt ctgccagcac tgcctatttg cagatcaaca acctcaaaaa 240
tgaggacacg gctacatatt tctgtgcaag attggaggtt cggggctatg ctatggacta 300
t 301
Claims (4)
1. An antihuman CXCL-2 monoclonal antibody or an antibody fragment thereof has amino acid variable region sequences shown as SEQ ID NO 7 and SEQ ID NO 8 in a sequence table respectively, and encoding gene sequences shown as SEQ ID NO 9 and SEQ ID NO 10 in the sequence table respectively.
2. An anti-human CXCL-2 monoclonal antibody or an antibody fragment thereof, characterized in that: the monoclonal antibody or antibody fragment comprises an antibody light chain comprising the complementarity determining region CDR1-3 and an antibody heavy chain comprising CDR 1-3:
light chain CDR1 has the amino acid sequence shown in SEQ ID NO. 1;
light chain CDR2 has the amino acid sequence shown in SEQ ID NO. 2;
light chain CDR3 has the amino acid sequence shown in SEQ ID NO. 3;
heavy chain CDR1 has the amino acid sequence shown in SEQ ID NO. 4;
heavy chain CDR2 has the amino acid sequence shown in SEQ ID NO. 5;
heavy chain CDR3 has the amino acid sequence shown in SEQ ID NO. 6.
3. The monoclonal antibody or antibody fragment thereof of claim 1 or 2, characterized in that: the monoclonal antibody or antibody fragment thereof includes single chain antibodies, diabodies, chimeric antibodies, humanized antibodies, and derivatives, functional equivalents or homologs of the foregoing.
4. Use of the monoclonal antibody or antibody fragment thereof according to claim 1 or 2 for the preparation of a medicament for the treatment of an immunological or infectious disease.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011066422.0A CN112358547A (en) | 2020-09-30 | 2020-09-30 | Anti-human CXCL-2 monoclonal antibody 3-D3 and coding gene and application thereof |
| PCT/CN2020/136276 WO2022068078A1 (en) | 2020-09-30 | 2020-12-14 | Anti-human cxcl-2 monoclonal antibody 3-d3, and coding gene and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011066422.0A CN112358547A (en) | 2020-09-30 | 2020-09-30 | Anti-human CXCL-2 monoclonal antibody 3-D3 and coding gene and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112358547A true CN112358547A (en) | 2021-02-12 |
Family
ID=74507017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011066422.0A Pending CN112358547A (en) | 2020-09-30 | 2020-09-30 | Anti-human CXCL-2 monoclonal antibody 3-D3 and coding gene and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112358547A (en) |
| WO (1) | WO2022068078A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070160574A1 (en) * | 2000-04-12 | 2007-07-12 | Ahmed Merzouk | Design of CXC chemokine analogs for the treatment of human diseases |
| US20080227711A1 (en) * | 2005-10-31 | 2008-09-18 | Laboratoires Serono Sa | Cxc-Chemokine Antagonists |
| CN107034272A (en) * | 2016-12-14 | 2017-08-11 | 河北医科大学第四医院（河北省肿瘤医院） | Applications of the CXCL2 in diagnosis or treatment adenocarcinoma of lung instrument is prepared |
| CN109134652A (en) * | 2013-03-15 | 2019-01-04 | 伊莱利利公司 | Pan-ELR+CXC chemotactic factor (CF) antibody |
| CN109526229A (en) * | 2016-07-08 | 2019-03-26 | Tak循环株式会社 | Screen prevention or the therapeutic agent of the prevention of the disease as caused by interleukin-6, interleukin-13, TNF, G-CSF, CXCL1, CXCL2 or CXCL5 or the method for therapeutic agent and the disease as caused by interleukin-6, interleukin-13, TNF, G-CSF, CXCL1, CXCL2 or CXCL5 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0016138D0 (en) * | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
| AU2003262051B2 (en) * | 2002-09-12 | 2008-09-25 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human antihuman MCP-1 antibody and antibody fragment thereof |
| PA8675801A1 (en) * | 2005-05-19 | 2006-12-07 | Centocor Inc | ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES |
| CA2692392A1 (en) * | 2007-06-29 | 2009-01-08 | Centocor Ortho Biotech Inc. | Anti- mcp-1 antibodies, compositions, methods and uses |
-
2020
- 2020-09-30 CN CN202011066422.0A patent/CN112358547A/en active Pending
- 2020-12-14 WO PCT/CN2020/136276 patent/WO2022068078A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070160574A1 (en) * | 2000-04-12 | 2007-07-12 | Ahmed Merzouk | Design of CXC chemokine analogs for the treatment of human diseases |
| US20080227711A1 (en) * | 2005-10-31 | 2008-09-18 | Laboratoires Serono Sa | Cxc-Chemokine Antagonists |
| CN109134652A (en) * | 2013-03-15 | 2019-01-04 | 伊莱利利公司 | Pan-ELR+CXC chemotactic factor (CF) antibody |
| CN109526229A (en) * | 2016-07-08 | 2019-03-26 | Tak循环株式会社 | Screen prevention or the therapeutic agent of the prevention of the disease as caused by interleukin-6, interleukin-13, TNF, G-CSF, CXCL1, CXCL2 or CXCL5 or the method for therapeutic agent and the disease as caused by interleukin-6, interleukin-13, TNF, G-CSF, CXCL1, CXCL2 or CXCL5 |
| CN107034272A (en) * | 2016-12-14 | 2017-08-11 | 河北医科大学第四医院（河北省肿瘤医院） | Applications of the CXCL2 in diagnosis or treatment adenocarcinoma of lung instrument is prepared |
Non-Patent Citations (5)
| Title |
|---|
| ANNA MOLES等: "A TLR2/S100A9/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse", 《JOURNAL OF HEPATOLOGY》 * |
| CHAO-CHAO QIN等: "Macrophage inflammatory protein-2 as mediator of inflammation in acute liver injury", 《WORLD J GASTROENTEROL》 * |
| CM HOGABOAM等: "Macrophage inflammatory protein-2 gene therapy attenuates adenovirus- and acetaminophen-mediated hepatic injury", 《GENE THERAPY》 * |
| KIMIHIDE NAKAMURA等: "Macrophage in¯ammatory protein-2 induced by TNF-a plays a pivotal role in concanavalin A-induced liver injury in mice", 《JOURNAL OF HEPATOLOGY》 * |
| 梁法生等: "趋化因子MIP-2在大鼠肝缺血/再灌注损伤后的表达", 《中国普通外科杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022068078A1 (en) | 2022-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110272490B (en) | Targeted CTLA-4 antibody, preparation method and application thereof | |
| WO2021197171A1 (en) | Anti-gdf15 neutralizing monoclonal antibody and use thereof | |
| CN105008521A (en) | Methods modulating immunoregulatory effect of stem cells | |
| CN106957366B (en) | C5aR antibody and preparation method and application thereof | |
| CN108367068B (en) | anti-S100A8 for the treatment of leukemia | |
| EP3000827A1 (en) | Anti-tnf-alpha/cxcl10 double-targeting antibody and use thereof | |
| CN112375147B (en) | Anti-human YKL-40 neutralizing monoclonal antibody and preparation and application thereof | |
| CN110117329A (en) | Fused polypeptide and application thereof comprising chemotactic factor (CF) and binding partners | |
| CN113248616B (en) | Chimeric antigen receptor targeting GPC3 and uses thereof | |
| WO2018082590A1 (en) | Tumor immunotherapy target and application thereof | |
| CN112210005A (en) | anti-C5 humanized monoclonal antibody with low immunogenicity and low ADCC/CDC function and application thereof | |
| CN111793134A (en) | Medicine, tumor vaccine and inhibitor for cancer treatment | |
| WO2024056098A1 (en) | Nkg2d-nkp46 cell adapter molecule and use thereof | |
| WO2020227194A1 (en) | Interferon regulatory factor 5 inhibitors and uses thereof | |
| CN112358547A (en) | Anti-human CXCL-2 monoclonal antibody 3-D3 and coding gene and application thereof | |
| CN117003877A (en) | Prdx1IgG neutralizing antibody, preparation method thereof and application thereof in preparation of acute organ injury or sepsis medicine | |
| CN114917329B (en) | Combination of anti-CD 87 antibody and anti-PD 1 antibody for treating gastric cancer | |
| CN113980133B (en) | Antibody and application thereof in anti-tumor | |
| KR20230167026A (en) | T cells co-expressing STAR for CXCR2 and GPC3, and uses thereof | |
| CN112961826B (en) | Application of transcription factor ZHX2 in NK cell regulation | |
| CN109750002B (en) | Hybridoma cell strain, monoclonal antibody secreted by hybridoma cell strain and having activity of inhibiting tumor progression and application of monoclonal antibody | |
| KR100958943B1 (en) | Pharmaceutical composition for the prevention or treatment of TGFb1-related diseases comprising down regulators of Galpha 12/Galpha 13 protein function | |
| CN113597315A (en) | Medicament for treating and preventing glioma, brain tumor malignancy marker, brain tumor prognosis marker, method for determining brain tumor malignancy and prognosis, and antibody for inhibiting tumor proliferation | |
| CN111234021B (en) | anti-CCR 5 antibody and application thereof in treating tumors | |
| CN111072781B (en) | DR-scFv capable of treating kidney interstitial fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210212 |
|
| WD01 | Invention patent application deemed withdrawn after publication |